| Cat. No. |
Product Name |
Information |
| PC-72819 |
SID7969543
SF-1/NR5A1 inhibitor
|
SID7969543 is a potent, selective and cell penetrant inhibitor of steroidogenic factor 1 (SF-1/NR5A1) with IC50 of 760 nM, also selectively targets KMT2A-rearranged (KMT2A-r) leukemia cells. |
| PC-72817 |
BACH2 inhibitor compound 8
BACH2/BACH1 inhibitor
|
BACH2 inhibitor compound 8 is a potent, dual BACH2/BACH1 inhibitor. |
| PC-72813 |
SOCS1 inhibitor 20
SOCS1 inhibitor
|
SOCS1 inhibitor 20 is a specific, cell-permeable phosphotyrosine peptide that target the SH2 domain of SOCS1 (Suppressor of cytokine signaling 1) with IC50 of 20 nM (hSOCS1) |
| PC-72812 |
TLX agonist 10
TLX (NR2E1) agonist
|
TLX agonist 10 is potent, selective agonist of the orphan nuclear receptor tailless homologue (TLX, NR2E1) with pEC50 of 6.6. |
| PC-72801 |
HB007
SUMO1 degrader
|
HB007 (HB-007) is a small-molecule degrader of the small ubiquitin-related modifier 1 (SUMO1) with anticancer potency in vitro and in vivo. |
| PC-72788 |
S62798
TAFIa inhibitor
|
S62798 (S 62798) is a highly selective human, mouse and rat TAFIa (Thrombin Activatable Fibrinolysis Inhibitor) inhibitor with IC50 of 11, 270, 178 nM respectively. |
| PC-72775 |
MTDH-SND1 inhibitor C26-A6
MTDH-SND1 inhibitor
|
MTDH-SND1 inhibitor C26-A6 is a specific inhibitor that disrupts the protein-protein interaction (PPI) between MTDH and SND1. |
| PC-72765 |
DC-SX029
SNX10 inhibitor
|
DC-SX029 is a new small-molecule sorting nexin 10 (SNX10) inhibitor (KD=0.935 uM), blocks the SNX10-PIKfyve interaction, decreases TBK1/c-Rel signaling activation. |
| PC-72762 |
CVN424
GPR6 inverse agonist
|
CVN424 (CVN 424) is a highly potent, selective, brain-penetrant, orally active GPR6 inverse agonist with EC50 of 38 nM. |
| PC-72748 |
PDDC
nSMase2 inhibitor
|
PDDC is the first potent, selective, orally-available, and brain-penetrable nSMase2 (neutral sphingomyelinase 2) inhibitor with pIC50 of 6.57. |
| PC-72746 |
Sari 59-801
|
SaRI 59-801 is an orally effective hypoglycemic compound, decreases blood glucose in several species and to elevate plasma insulin in rats and mice. |
| PC-72745 |
CHD1Li 6.11
CHD1L inhibitor
|
CHD1Li 6.11 (OTI-611) is a first in class, orally bioavailable oncogenic CHD1L inhibitor with 3.3 uM (CHD1L-cat enzyme activity). |
